141 related articles for article (PubMed ID: 16061637)
21. Nit1 and Fhit tumor suppressor activities are additive.
Sun J; Okumura H; Yearsley M; Frankel W; Fong LY; Druck T; Huebner K
J Cell Biochem; 2009 Aug; 107(6):1097-106. PubMed ID: 19479888
[TBL] [Abstract][Full Text] [Related]
22. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
23. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
He Z; Liu S; Guo M; Mao J; Hughson MD
Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
[TBL] [Abstract][Full Text] [Related]
24. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine.
Alleman WG; Tabios RL; Chandramouli GV; Aprelikova ON; Torres-Cabala C; Mendoza A; Rogers C; Sopko NA; Linehan WM; Vasselli JR
Clin Cancer Res; 2004 Oct; 10(20):7011-21. PubMed ID: 15501981
[TBL] [Abstract][Full Text] [Related]
25. Fhit loss-associated initiation and progression of neoplasia in vitro.
Karras JR; Schrock MS; Batar B; Zhang J; La Perle K; Druck T; Huebner K
Cancer Sci; 2016 Nov; 107(11):1590-1598. PubMed ID: 27513973
[TBL] [Abstract][Full Text] [Related]
26. A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred.
Iida K; Okimura Y; Takahashi K; Inomata S; Iguchi G; Kaji H; Chihara K
Int J Mol Med; 2004 Mar; 13(3):401-4. PubMed ID: 14767570
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin II type 2 receptor gene deficiency attenuates susceptibility to tobacco-specific nitrosamine-induced lung tumorigenesis: involvement of transforming growth factor-beta-dependent cell growth attenuation.
Kanehira T; Tani T; Takagi T; Nakano Y; Howard EF; Tamura M
Cancer Res; 2005 Sep; 65(17):7660-5. PubMed ID: 16140932
[TBL] [Abstract][Full Text] [Related]
28. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells.
Nishizaki M; Sasaki J; Fang B; Atkinson EN; Minna JD; Roth JA; Ji L
Cancer Res; 2004 Aug; 64(16):5745-52. PubMed ID: 15313915
[TBL] [Abstract][Full Text] [Related]
29. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
30. Loss of FHIT function in lung cancer and preinvasive bronchial lesions.
Sozzi G; Pastorino U; Moiraghi L; Tagliabue E; Pezzella F; Ghirelli C; Tornielli S; Sard L; Huebner K; Pierotti MA; Croce CM; Pilotti S
Cancer Res; 1998 Nov; 58(22):5032-7. PubMed ID: 9823304
[TBL] [Abstract][Full Text] [Related]
31. Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice.
Kleymenova E; Everitt JI; Pluta L; Portis M; Gnarra JR; Walker CL
Carcinogenesis; 2004 Mar; 25(3):309-15. PubMed ID: 14604887
[TBL] [Abstract][Full Text] [Related]
32. FHIT gene therapy prevents tumor development in Fhit-deficient mice.
Dumon KR; Ishii H; Fong LY; Zanesi N; Fidanza V; Mancini R; Vecchione A; Baffa R; Trapasso F; During MJ; Huebner K; Croce CM
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3346-51. PubMed ID: 11248081
[TBL] [Abstract][Full Text] [Related]
33. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
34. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
35. Early loss of Fhit in the respiratory tract of rodents exposed to environmental cigarette smoke.
D'Agostini F; Izzotti A; Balansky R; Zanesi N; Croce CM; De Flora S
Cancer Res; 2006 Apr; 66(7):3936-41. PubMed ID: 16585223
[TBL] [Abstract][Full Text] [Related]
36. Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood.
Tan S; Sun C; Wei X; Li Y; Wu Y; Yan Z; Feng F; Wang J; Wu Y
Exp Lung Res; 2013; 39(4-5):182-90. PubMed ID: 23614702
[TBL] [Abstract][Full Text] [Related]
37. A mouse model of the fragile gene FHIT: From carcinogenesis to gene therapy and cancer prevention.
Zanesi N; Pekarsky Y; Croce CM
Mutat Res; 2005 Dec; 591(1-2):103-9. PubMed ID: 16085127
[TBL] [Abstract][Full Text] [Related]
38. Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival.
Capuzzi D; Santoro E; Hauck WW; Kovatich AJ; Rosato FE; Baffa R; Huebner K; McCue PA
Cancer; 2000 Jan; 88(1):24-34. PubMed ID: 10618602
[TBL] [Abstract][Full Text] [Related]
39. Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies.
Ishii H; Dumon KR; Vecchione A; Fong LY; Baffa R; Huebner K; Croce CM
JAMA; 2001 Nov; 286(19):2441-9. PubMed ID: 11712940
[TBL] [Abstract][Full Text] [Related]
40. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
